Evaluation of immunoglobulin G and immunoglobulin G subclass levels in serum of antimuscle specific kinase and anti-acetylcholine receptor antibody positive myasthenia gravis patients


  • Sander Haas, de




Due to policy boundaries, the results and conclusions of my thesis cannot be disclosed in this paper. Instead this paper will provide background information about myasthenia gravis (MG) and the role of immunoglobulin G (IgG) antibodies in autoimmune MG. Additionally, previous literature will be discussed to elucidate the aim and relevance of my internship project. During the internship, total IgG and IgG subclass (IgG1, IgG2, IgG3, and IgG4) concentrations were evaluated in serum of anti-muscle specific kinase antibody positive MG (MuSK-MG), anti-acetylcholine receptor antibody positive MG (AChR-MG) patients and compared with the total IgG and IgG subclass levels in healthy control serum.


Kandel E. Principles of Neural Science. Fifth Edition ed: McGraw-Hill Education; 2013. p. 307-30.

Kandel E. Principles of Neural Science. Fifth Edition ed: McGraw-Hill Education; 2013. p. 768-89.

Kandel E. Principles of Neural S cience. Fifth Edition ed: McGraw-Hill Education; 2013. p. 177-88.

Wu H, Xiong WC, Mei L. To build a synapse: signaling pathways in neuromuscular junction assembly. Development. 2010;137(7):1017-33.

Keesey JC. “Crisis” in myasthenia gravis: An historical perspective. Muscle & nerve. 2002;26(1):1-3.

Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. Journal of Clinical Investigation. 2006;116(11):2843.

Koneczny I, Cossins J, Vincent A. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. J Anat. 2014;224(1):29-35.

Verschuuren J, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P, et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and lowdensity lipoprotein receptor-related protein 4. Autoimmunity reviews. 2013;12(9):918-23.

Niks EH, Kuks JB, Verschuuren JJ. Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands. Journal of Neurology, Neurosurgery & Psychiatry. 2007;78(4):417-8.

Berrih-Aknin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. Journal of autoimmunity. 2014;52:90-100.

Tsiamalos P, Kordas G, Kokla A, Poulas K, Tzartos S. Epidemiological and immunological profile of muscle‐ specific kinase myasthenia gravis in Greece. European Journal of Neurology. 2009;16(8):925-30.

Niks E, Kuks J, Roep B, Haasnoot G, Verduijn W, Ballieux B, et al. Strong association of MuSK antibody– positive myasthenia gravis and HLA-DR14-DQ5. Neurology. 2006;66(11):1772-4.

Maniaol AH, Elsais A, Lorentzen AR, Owe JF, Viken MK, Sæther H, et al. Late onset myasthenia gravis is associated with HLA DRB1* 15: 01 in the Norwegian population. PLoS One. 2012;7(5):e36603.

Gomez AM, Van Den Broeck J, Vrolix K, Janssen SP, Lemmens MA, Van Der Esch E, et al. Antibody effector mechanisms in myasthenia gravis – pathogenesis at the neuromuscular junction. Autoimmunity. 2010;43(5-6):353-70.

Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunology today. 1993;14(9):426-30.

Ha JC, Richman DP. Myasthenia gravis and related disorders: Pathology and molecular pathogenesis. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2015;1852(4):651-7.

Schroeder HW, Cavacini L. Structure and function of immunoglobulins. Journal of Allergy and Clinical Immunology. 2010;125(2):S41-S52.

Nirula A, Glaser SM, Kalled SL, Taylora FR. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Current opinion in rheumatology. 2011;23(1):119-24.

Van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 2007;317(5844):1554-7.

Huijbers M, Querol L, Niks E, Plomp J, Maarel S, Graus F, et al. The expanding field of IgG4‐mediated neurological autoimmune disorders. European Journal of Neurology. 2015.

Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature medicine. 2001;7(3):365-8.

Huijbers MG, Zhang W, Klooster R, Niks EH, Friese MB, Straasheijm KR, et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proceedings of the National Academy of Sciences. 2013;110(51):20783-8.

Koneczny I, Cossins J, Waters P, Beeson D, Vincent A. MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters. 2013.

Funakoshi T, Lunardon L, Ellebrecht CT, Nagler AR, O’Leary CE, Payne AS. Enrichment of total serum IgG4 in patients with pemphigus. Br J Dermatol. 2012;167(6):1245-53.

Futei Y, Amagai M, Ishii K, Kuroda-Kinoshita K, Ohya K, Nishikawa T. Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus. Journal of Dermatological Science. 2001;26(1):55-61.

Islam AD, Selmi C, Datta-Mitra A, Sonu R, Chen M, Gershwin ME, et al. The changing faces of IgG4-related disease: Clinical manifestations and pathogenesis. Autoimmunity Reviews. Forthcoming 2015

Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol. 2005;23:367-86.

Traggiai E, Puzone R, Lanzavecchia A. Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine. 2003;21:S35-S7

Aalberse R, Stapel S, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clinical & Experimental Allergy. 2009;39(4):469-77.

De Boer B, Kruize Y, Rotmans PJ, Yazdanbakhsh M. Interleukin-12 suppresses immunoglobulin E production but enhances immunoglobulin G4 production by human peripheral blood mononuclear cells. Infection and immunity. 1997;65(3):1122-5.

Wood N, Bourque K, Donaldson DD, Collins M, Vercelli D, Goldman SJ, et al. IL-21 effects on human IgE production in response to IL-4 or IL-13. Cellular immunology. 2004;231(1):133-45.

Aalberse RC, Platts-Mills TA. How do we avoid developing allergy: Modifications of the T H 2 response from a B-cell perspective. Journal of allergy and clinical immunology. 2004;113(5):983-6.

Robinson DS, Larché M, Durham SR. Tregs and allergic disease. Journal of Clinical Investigation. 2004;114(10):1389.

Yilmaz V, Oflazer P, Aysal F, Durmus H, Poulas K, Yentur SP, et al. Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK. PLoS ONE. 2015: 10(4):e0123546

Guptill JT, John SY, Sanders DB, Guidon AC, Juel VC, Massey JM, et al. Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. Neurology-Neuroimmunology Neuroinflammation. 2015;2(2):e77.

Liu Y, Wang W, Li J. Evaluation of serum IgG subclass concentrations in myasthenia gravis patients. International Journal of Neuroscience. 2011;121(10):570-4.